GNMSF - Unum Therapeutics Updates Proposed IPO Terms
Company Recap
Cambridge, MA-based Unum Therapeutics (UNUM) was founded in 2014. The company has developed an antibody-coupled T-cell receptor [ACTR] platform that causes an individual’s cytotoxic T-lymphocytes [CTLs] to kill tumor cells when combined with tumor-specific antibodies.
Management is headed by CEO Charles Wilson who also founded the company. Prior to Unum, Wilson was the Vice President, Global Head of Strategic Alliances of Novartis from 2008 - 2014 and CTO/Vice President Alliance Management of Archemix from 2001 - 2008.
The firm’s lead program (based on ACTR technology) is in Phase I clinical testing